Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer

Oncologist

Volumn 10, Issue 9, 2005, Pages 665-685

  Eniu, Alexandru ^a   Palmieri, Frances M ^b   Perez, Edith A ^b  

^a Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^b MAYO CLINIC   (United States)

Author keywords

Breast cancer; Chemotherapy; Metastatic disease; Taxanes

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE PHOSPHATE SODIUM; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APPETITE DISORDER; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CLINICAL TRIAL; DACRYORRHEA; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; EMBOLISM; EYE DISEASE; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEADACHE; HEARING DISORDER; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; INFECTION; LEUKOPENIA; LUNG TOXICITY; LYMPHOCYTOPENIA; METASTASIS; MOOD DISORDER; MOTOR NEURON DISEASE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PRURITUS; RASH; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SKIN DISEASE; SKIN TOXICITY; SMELLING DISORDER; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 27644497583     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-9-665     Document Type: Article

References (101)

1. American Cancer Society. Cancer Facts and Figures 1996-2004. Available at http://www.cancer.org. Accessed January 31, 2005.
2. Olin JJ, Muss HB. New strategies for managing metastatic breast cancer. Oncology (Williston Park) 2000;14:629-641; discussion 642-644, 647-648.
3. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-291.
4. D'Andrea GM, Seidman AD. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Semin Oncol 1997;24(suppl 13):S13-27-S13-44.
5. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-1805.
6. Valero V, Holmes FA, Walters RS et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894.
7. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-592.
8. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-2354.
9. Paridaens R, Biganzoli L, Bruning P et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastastic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000;18:724-733.
10. Nabholtz JM, Thuerlimann B, Bezwoda WR et al. Docetaxel vs. mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncol (Williston Park) 1997;11(suppl 8):25-30.
11. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-1867.
12. Ravdin PM, Burris HA 3rd, Cook G et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885.
13. Seidman AD, Reichman BS, Crown JP et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13:1152-1159.
14. Seidman AD, Tiersten A, Hudis C et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-2581.
15. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355:1176-1178.
16. Bristol-Myers Squibb Company. Taxol Full Prescribing Information. Available at http://www.bms.com. Accessed April 4, 2005.
17. Van Poznak C, Seidman AD. Critical review of current treatment strategies for advanced hormone insensitive breast cancer. Cancer Invest 2002;20(suppl 2):1-14.
18. Kouroussis C, Agelaki S, Mavroudis D et al. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2000;46:488-492.
19. Minami H, Sasaki Y, Tahara M et al. Phase I and pharmacological study of weekly docetaxel in comparison with administration every 3 weeks. Proc Am Soc Clin Oncol 2002;21:122a.
20. Tomiak E, Piccart MJ, Kerger J et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994;12:1458-1467.
21. Hainsworth JD, Burris HA 3rd, Erland JB et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168.
22. Löffler TM, Freund W, Dröge C et al. Activity of weekly taxotere (TXT) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:113a.
23. Briasoulis E, Karavasilis V, Anastasopoulos D et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999;10:701-706.
24. Lück HJ, Donne S, Glaubitz M et al. Phase I study of weekly docetaxel (Taxotere) in heavily pretreated breast cancer patients. Eur J Cancer 1997;33:S158.
25. Scholz U, Luck HJ, Rittershaus A et al. Weekly docetaxel treatment in metastatic breast cancer: a phase I/II study. Breast Cancer Res Treat 1998;50:262.
26. Jackisch C, Eibach H, Knuth A et al. Phase II trial of docetaxel weekly as dose dense treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000;18:417a.
27. Kim Y, Takatsuka Y, Tanigawara Y et al. Weekly docetaxel for patients with recurrent breast cancer: clinical results and pharmacokinetic/ pharmacodynamic assessment. Proc Am Soc Clin Oncol 2000;18:436a.
28. Ford HER, Miles D, Makris A et al. A phase II study of a weekly docetaxel schedule in patients with anthracycline pretreated metastatic breast cancer. Ann Oncol 2002;13(suppl 5):65.
29. Ramos M, Gonzalez-Ageitos A, Amenedo M et al. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 2003;15:192-197.
30. Mey U, Gorschluter M, Ziske C et al. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 2003;14:233-238.
31. Maisano R, Mare M, Zavattieri M et al. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 2003;23:1923-1926.
32. Kuroi K, Bando H, Saji S et al. Protracted administration of weekly docetaxel in metastatic breast cancer. Oncol Rep 2003;10:1479-1484.
33. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
34. Stemmler J, Mair W, Stauch M et al. Weekly docetaxel with or without corticosteroid premedication as first or second-line treatment in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002;21:58a.
35. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002;13:286-292.
36. Hainsworth JD, Burris HA 3rd, Yardley DA et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001;19:3500-3505.
37. Estevez LG, Cuevas JM, Anton A et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003;9:686-692.
38. D'Hondt R, Paridaens R, Wildiers H et al. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 2004;15:341-346.
39. Tabernero J, Climent MA, Lluch A et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-1365.
40. Sedky L, Saad I, Hashem B et al. Weekly docetaxel vs. every 3-week in advanced breast cancer: results of a pilot comparative study. Proc Am Soc Clin Oncol 2002;20:2013a.
41. Ito Y, Aiba K, Horikoshi N et al. Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer. Int J Clin Oncol 2001;6:242-247.
42. Wenzel C, Locker GJ, Pluschnig U et al. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol 2002;50:155-159.
43. Yardley DA, Whitworth P, Greco FA et al. Neoadjuvant gemcitabine, epirubicin, and docetaxel (GET). Preliminary results from a multi-center phase II trial in inflammatory and locally advanced breast cancer. Breast Cancer Res Treat 2003;82(suppl 1):S54.
44. Holmes FA, Blum JL, Kruger S et al. Phase II study of weekly pegylated liposomal doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 2003;82(suppl 1):S130.
45. Brugnatelli S, Danova M, De Bella MT et al. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase I study. Oncology 2002;62:33-38.
46. Frasci G, Comella P, D'Aiuto G et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 2000;11:367-371.
47. Fountzilas F, Nicolaides C, Bafaloukos D et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study. Cancer Invest 2000;18:503-509.
48. Mavroudis D, Malamos N, Alexopoulos A et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann Oncol 1999;10:211-215.
49. Laufman L, Spiridonidis C, Carman L et al. Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docetaxel (DOC) in patients (pts) with metastatic breast cancer (MBC): a phase II study. Pro Am Soc Clin Oncol 2000;18:1968a.
50. Kornek GV, Ulrich-Pur H, Penz M et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001;19:621-627.
51. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
52. Soule SE, Miller KD, Porcu P et al. Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. Ann Oncol 2002;13:1612-1615.
53. Nicholson BP, Thor AD, Goldstein LJ et al. A phase II trial of weekly Taxotere and Herceptin in advanced breast cancer. Presented at the Chemotherapy Foundation Symposium XVIII, New York, NY, November 8-11, 2000.
54. Raab G, Brugger W, Harbeck N et al. Multi-center randomized phase II study of docetaxel (Doc) given q3w vs. q1wk plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracycline pretreated metastatic breast cancer (MBC). Breast Cancer Res Treat 2002;76(suppl 1):S114.
55. Tedesco KL, Thor AD, Johnson DH et al. Docetaxel combined with trastuzumab is an active regimen in HER-23+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004;22:1071-1077.
56. Bines J, Murad A, Lago S et al. Weekly docetaxel (Taxotere) and trastuzumab (Herceptin) as primary therapy in stage III, HER-2 overexpressing breast cancer - a Brazilian multi-center study. Breast Cancer Res Treat 2003;82(suppl 1):S56.
57. Raff JP, Rajdev L, Malik U et al. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 2004;2:420-427.
58. Yardley DA, Greco FA, Porter LL et al. First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2 + MBC): a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2004;22(suppl):37S.
59. Wenzel C, Hussian D, Bartsch R et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004;130:400-404.
60. Meier CR, Illiger HJ, Steder M et al. Weekly vinorelbine (VIN) vs. weekly docetaxel (DOC) for metastatic breast cancer failing anthracyclines. Planned interim analysis of a randomized trial. J Clin Oncol 2004;22(suppl):62s.
61. Seidman AD, Hudis CA, Albanel J et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-3361.
62. Wist EA, Sommer HH, Ostenstad B et al. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004;43:11-14.
63. Lombardi D, Crivellari D, Scuderi C et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori 2004;90:285-288.
64. Sato K, Inoue K, Saito T et al. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). Jpn J Clin Oncol 2003;33:371-376.
65. Nishi T, Yamanaka E, Yamasaki M et al. [Efficacy and safety of weekly taxol (TXL) for advanced recurrent breast cancer evaluated in a multicenter cooperative clinical trial.] Gan To Kagaku Ryoho 2004;31:897-901. Japanese.
66. Baltali E, Altundag K, Ozisik Y et al. Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients. Tohoku J Exp Med 2004;203:205-210.
67. Gori S, Mosconi AM, Basurtol C et al. Weekly paclitaxel in metastatic breast cancer patients: a phase II study. Tumori 2002;88:470-473.
68. Akerley W, Sikov WM, Cummings F et al. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol 1997;24(suppl 17):S17-87-S17-90.
69. Perez EA, Vogel CL, Irwin DH et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216-4223.
70. Perez EA, Vogel CL, Irwin DH et al. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 2002;73:85-88.
71. ten Tije AJ, Smorenburg CH, Seynaeve C et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004;40:352-357.
72. Sikov WM, Akerley W, Kahanic S et al. Multicenter, 3-arm randomized study of high-dose weekly paclitaxel (HDWP) versus standard-dose weekly paclitaxel (SWDP) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002;21:34a.
73. Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: phase III study of weekly (w) paclitaxel (p) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 2004;22:512a.
74. Panday VR, ten Bokkel Huinink WW, Rosing H et al. Phase I and pharmacologic study of weekly doxorubicin and 1h infusional paclitaxel in patients with advanced breast cancer. Anticancer Drugs 1998;9:665-673.
75. Kohler U, Olbricht SS, Fuechsel G et al. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study. Semin Oncol 1997;24(suppl 17):S17-40-S17-43.
76. Cals L, Nouyrigat P, Tchiknavorian X et al. Neoadjuvant weekly paclitaxel, and epirubicin (PE) in patients with inflammatory and T4 breast cancer (IBC-T4BC): result of a VAR Cancer Society trial. J Clin Oncol 2004;22(suppl):56S.
77. Schwonzen M, Kurbacher CM, Mallmann P et al. doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000;11:681-685.
78. Fulfaro F, Valerio MR, Badalamenti G et al. Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients. J Clin Oncol 2004;22(suppl):53S.
79. Frasci G, D'Aiuto G, Comella P et al. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group. Breast Cancer Res Treat 1999;56:239-252.
80. Frasci G, D'Aiuto G, Comella P et al. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. Southern Italy Cooperative Oncology Group (SICOG) phase II study. Breast Cancer Res Treat 2000;62:87-97.
81. Frasci G, D'Aiuto G, Comella P et al. Two-month cisplatin-epirubicin- paclitaxel (PET) weekly administration for the treatment of large operable breast cancer. SICOG 0105 phase II study. J Clin Oncol 2004;22(suppl):27S.
82. Comella G, D'Aiuto G, Comella P et al. Comparison of weekly cisplatin-epirubicin-paclitaxel (PET) with triweekly epirubicin-paclitaxel (ET) in locally advanced breast cancer (LABC). SICOG 9908 phase III trial. J Clin Oncol 2004;22(suppl):5S.
83. Maiorino L, Maiorino G, Frasci G et al. Weekly cisplatin-epirubicin- paclitaxel (PET) vs. tri-weekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Interim analysis of the SICOG 9908 phase III trial. J Clin Oncol 2004;22(suppl):37S.
84. Loesch D, Robert N, Asmar L et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002;20:3857-3864.
85. Robert N, Loesch D, Lindquist D et al. A randomized, phase II trial of weekly paclitaxel versus weekly paclitaxel + carboplatin for first-line metastatic breast cancer. Breast Cancer Res Treat 2003;82(suppl 1):S129.
86. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
87. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001;12:1545-1551. (1B)
88. Christodoulou C, Klouvas G, Pateli A et al. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. Anticancer Res 2003;23:737-744.
89. Luftner D, Henschke P, Flath B et al. Serum HER-2 as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. Anticancer Res 2004;24:895-906.
90. John M, Kriebel-Schmitt R, Stauch M et al. Weekly paclitaxel plus trastuzumab shows promising efficacy in advanced breast cancer. Breast Cancer Res Treat 2003;82(suppl 1):S49. (2B)
91. Gasparini G, Morabito A, De Sio L et al. Preliminary clinical results of a randomized phase IIb study of weekly paclitaxel (PCT) trastuzumab (T) as first-line therapy of patients (pts) with HER2/neu positive metastatic breast cancer (MBC). Breast Cancer Res Treat 2003;82(suppl 1):S51.
92. Gori S, Colozza M, Mosconi AM et al. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 2004;90:36-40.
93. Burris H 3rd, Yardley D, Jones S et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22:1621-1629.
94. Trigo J, Climent MA, Lluch A et al. Liposomal doxorubicin Myocet in combination with Herceptin and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer: a phase II study. Breast Cancer Res Treat 2003;82(suppl 1):S83.
95. Perez EA, Rowland KM, Suman VJ et al. N98-32-52: efficacy and tolerability of two schedules of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer: a North Central Cancer Treatment Group randomized phase II trial. Breast Cancer Res Treat 2003;82(suppl 1):S47.
96. Sawaki M, Ito Y, Hashimoto D et al. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori 2004;90:36-39.
97. Gennari A, Guarneri V, Landucci E et al. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. Clin Breast Cancer 2002;3:346-352.
98. Dang CT, D'Andrea GM, Moynahan ME et al. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004;10:5754-5761.
99. Frasci G, Comella P, D'Aiuto G et al. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res Treat 1998;49:13-26.
100. Bouillet T, Saintigny P, Levy E et al. Weekly paclitaxel (P) combined with biweekly vinorelbine (V) in metastatic breast cancer (MBC): final results of a clinical phase II study. J Clin Oncol 2004;22(suppl):72S.
101. Ghosn M, Chahine G, Kattan J et al. Phase II study of sequential administration of vinorelbine-capecitabine combination followed by weekly docetaxel as first line chemotherapy for advanced breast cancer. J Clin Oncol 2004;22:80S.